DHR vs GS: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and The Goldman Sachs Group, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
Danaher Corporation · Healthcare
$174.04
+13.2% upside to fair value
Grade B
VS
The Goldman Sachs Group, Inc. · Financial Services
$926.55
-98.0% upside to fair value
Grade D
QuantHub Verdict
DHR has more upside to fair value
(+13.2%).
GS trades at a lower forward P/E
(15.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
GS |
| Current Price |
$174.04 |
$926.55 |
| Fair Value Estimate |
$197.01 |
$18.16 |
| Upside to Fair Value |
+13.2%
|
-98.0%
|
| Market Cap |
$123.2B |
$275.0B |
| Forward P/E |
33.4x
|
15.6x
|
| EV / EBITDA |
20.3x
|
30.6x
|
| Price / Sales |
5.0x
|
2.5x
|
| Price / FCF |
23.3x
|
-5.8x
|
| Revenue Growth YoY |
+3.7%
|
-45.4%
|
| Gross Margin |
60.7%
|
55.5%
|
| Operating Margin |
21.0%
|
20.5%
|
| Return on Equity |
7.1%
|
14.6%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.3%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher Corporation is a diversified healthcare company focused on medical diagnostics, life sciences, and biotechnology, generating approximately $24 billion in revenue with a strong recurring revenue base of over 81%. The company benefits from a high gross margin of 60.7% and solid operating margin of 21%, supported by a seasoned management team with a proven capital allocation track record inc…
The Goldman Sachs Group, Inc. operates as a leading global financial services firm specializing in investment banking, securities, investment management, and consumer banking. The company benefits from a high-quality business model characterized by strong brand recognition, deep client relationships, and a history of stable leadership. However, the stock is currently significantly overvalued, tra…
Accumulation Zones
| Metric |
DHR |
GS |
| Zone Low |
$147.76 |
$13.62 |
| Zone High |
$167.46 |
$15.44 |
| In Buy Zone? |
No
|
No
|